The Leukemia & Lymphoma Society has announced a $4.5 million collaboration with the Mark Foundation for Cancer Research and the Paul G. Allen Frontiers Group focused on the development of new therapies for blood cancer.
Each organization has committed $1.5 million to launch the LLS Blood Cancer Discoveries Grants Program, which over the next three years will award up to six grants of $750,000 in support of research aimed at understanding the biological underpinnings of various blood cancers, including the mechanisms that cause them to develop, grow, and become resistant to treatments.
"These grants represent a significant investment in cancer discovery research that has a clear line of sight to better outcomes for patients," said Mark Foundation CEO Michele Cleary. "In collaboration with our partners at LLS and the Paul G. Allen Frontiers Group, the Mark Foundation is pleased to help address the critical need for this type of funding, and we look forward to seeing the results of the science it will support."
"LLS's investment in research over the past fifteen years is translating into remarkable improvements in outcomes for blood cancer patients," said LLS chief scientific officer Lee Greenberger. "Over the past two and a half years alone, we've seen the FDA approve forty-eight therapies in the blood cancers, and LLS's investment in research played a role in forty-two of these. However, cures still remain elusive for many aggressive blood cancers. This new program, made possible through this collaboration, seeks to ignite that next wave of discoveries and fill the pipeline that eventually will become the translational research of the next five to ten years."